Article Details

As Organon charts post-spinoff future, Merck's $9B cash infusion could fund big M&A score

Retrieved on: 2021-05-04 21:11:15

Tags for this article:

Click the tags to see associated articles and topics

As Organon charts post-spinoff future, Merck's $9B cash infusion could fund big M&A score. View article details on hiswai:

Excerpt

With sales for Merck's women's health, biosimilar and older meds sagging in recent years, the drugmaker is gearing up to jettison those offerings in its ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up